흑색종 치료 시장 : 예측(2025-2030년)

The Melanoma Treatment Market is expected to grow from US$7.510 billion in 2025 to US$9.815 billion in 2030, at a CAGR of 5.50%.

In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.

Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally and caused by too much exposure to ultraviolet rays from the sun and indoor tanning. Based on therapy, targeted therapy is gaining market share due to fewer side effects and high efficiency rates.

Melanoma Treatment Market Growth Factors:

• Growing regulatory approvals

The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has had the highest impact on market growth. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.

Some of the market leaders in the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca.

Melanoma Treatment Companies:

• Merck & Co. Inc.
• Amgen Inc.
• Iovance Biotherapeutics, Inc.
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd.

Melanoma Treatment Market Segmentation:

By Type

• Cutaneous Melanoma
• Ocular Melanoma
• Mucosal Melanoma

By Therapy

• Surgery
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiation Therapy

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indoensia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MELANOMA TREATMENT MARKET BY TYPE

• 5.1. Introduction
• 5.2. Cutaneous Melanoma
• 5.3. Ocular Melanoma
• 5.4. Mucosal Melanoma

6. MELANOMA TREATMENT MARKET BY THERAPY

• 6.1. Introduction
• 6.2. Surgery
• 6.3. Immunotherapy
• 6.4. Targeted Therapy
• 6.5. Chemotherapy
• 6.6. Radiation Therapy

7. MELANOMA TREATMENT MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Merck & Co., Inc.
• 9.2. Amgen Inc.
• 9.3. Iovance Biotherapeutics, Inc.
• 9.4. Bristol-Myers Squibb
• 9.5. F. Hoffmann-La Roche Ltd
• 9.6. Eisai Co., Ltd.
• 9.7. Novartis AG
• 9.8. Pfizer Inc.
• 9.9. Sanofi
• 9.10. AstraZeneca

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations